{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:09:25Z","timestamp":1789708165426,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["TMU104-AE1-B16"],"award-info":[{"award-number":["TMU104-AE1-B16"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["N201709052"],"award-info":[{"award-number":["N201709052"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.breast.2021.02.011","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T05:47:42Z","timestamp":1614059262000},"page":"18-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4781-0281","authenticated-orcid":false,"given":"Yu-Ju","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Nan","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4199-0867","authenticated-orcid":false,"given":"Yu","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.breast.2021.02.011_bib1","first-page":"7","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA: Canc J Clin"},{"issue":"11","key":"10.1016\/j.breast.2021.02.011_bib2","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdq220","article-title":"Survival differences among women with de novo stage IV and relapsed breast cancer","volume":"21","author":"Dawood","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2021.02.011_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.breast.2016.10.005","article-title":"Improved survival in metastatic breast cancer 1985-2016","volume":"31","author":"Sundquist","year":"2017","journal-title":"Breast"},{"issue":"8","key":"10.1016\/j.breast.2021.02.011_bib4","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO\u2013ESMO international consensus guidelines for advanced breast cancer (ABC 4)\u2020\u2020These guidelines were developed by the European school of oncology (ESO) and the European society for medical oncology (ESMO)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"issue":"5s","key":"10.1016\/j.breast.2021.02.011_bib5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.6004\/jnccn.2018.0043","article-title":"NCCN guidelines updates: breast cancer","volume":"16","author":"Giordano","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw : J Natl Compr Canc Netw"},{"issue":"7","key":"10.1016\/j.breast.2021.02.011_bib6","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","article-title":"The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth","volume":"4","author":"Jordan","year":"2005","journal-title":"Mol Canc Therapeut"},{"issue":"9769","key":"10.1016\/j.breast.2021.02.011_bib7","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.breast.2021.02.011_bib8","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J\u00a0Clin Oncol : Off J Am Soc Clin Oncol."},{"issue":"3","key":"10.1016\/j.breast.2021.02.011_bib9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12282-017-0826-4","article-title":"Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine","volume":"25","author":"Pivot","year":"2018","journal-title":"Breast Canc"},{"key":"10.1016\/j.breast.2021.02.011_bib10","first-page":"117","article-title":"Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial","volume":"60","author":"Aftimos","year":"2016","journal-title":"Eur J Canc (Oxford, England : 1990"},{"issue":"1","key":"10.1016\/j.breast.2021.02.011_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2217\/fon-2018-0324","article-title":"Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study","volume":"15","author":"Barni","year":"2019","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.breast.2021.02.011_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/0284186X.2018.1497301","article-title":"Efficacy and toxicity of eribulin treatment in metastatic breast cancer patients","volume":"58","author":"Brems-Eskildsen","year":"2019","journal-title":"Acta Oncol"},{"issue":"12","key":"10.1016\/j.breast.2021.02.011_bib13","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1002\/ijc.32402","article-title":"Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program","volume":"145","author":"Jacot","year":"2019","journal-title":"Int J Canc"},{"key":"10.1016\/j.breast.2021.02.011_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.breast.2016.08.015","article-title":"Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France","volume":"30","author":"Hurtaud","year":"2016","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.breast.2021.02.011_bib15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1186\/s12885-017-3846-8","article-title":"Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study","volume":"17","author":"Iizumi","year":"2017","journal-title":"BMC Canc"},{"issue":"2","key":"10.1016\/j.breast.2021.02.011_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4143\/crt.2016.191","article-title":"Feasibility and efficacy of eribulin mesilate in Korean patients with metastatic breast cancer: Korean multi-center phase IV clinical study results","volume":"49","author":"Park","year":"2017","journal-title":"Canc Res Treat: Off J Kor Canc Assoc"},{"issue":"3","key":"10.1016\/j.breast.2021.02.011_bib17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10549-018-4778-y","article-title":"Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan","volume":"170","author":"Rau","year":"2018","journal-title":"Breast Canc Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2021.02.011_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40801-019-0150-8","article-title":"Use of a healthcare claims database for post-marketing safety assessments of eribulin in Japan: a comparative assessment with a prospective post-marketing surveillance study","volume":"6","author":"Sakata","year":"2019","journal-title":"Drugs - Real World Outc"},{"issue":"12","key":"10.1016\/j.breast.2021.02.011_bib19","first-page":"1200","article-title":"[Treatment out come of eribulin in patients with advanced or metastatic breast cancer who resistant to anthracycline and taxane]","volume":"44","author":"Tanaka","year":"2017","journal-title":"Gan to kagaku ryoho Canc Chemother"},{"issue":"5","key":"10.1016\/j.breast.2021.02.011_bib20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/1759-7714.12482","article-title":"Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice","volume":"8","author":"Tanaka","year":"2017","journal-title":"Thorac Canc"},{"issue":"32","key":"10.1016\/j.breast.2021.02.011_bib21","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1200\/JCO.2014.55.8437","article-title":"Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis","volume":"32","author":"Niraula","year":"2014","journal-title":"J\u00a0Clin Oncol : Off J Am Soc Clin Oncol."},{"issue":"11","key":"10.1016\/j.breast.2021.02.011_bib22","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.breast.2021.02.011_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10549-012-2326-8","article-title":"A\u00a0cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer","volume":"137","author":"Lopes","year":"2013","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2021.02.011_bib24","unstructured":"The PSMATCH Procedure [https:\/\/documentation.sas.com\/?docsetId=statug&docsetTarget=statug_psmatch_examples04.htm&docsetVersion=14.3&locale=en]."},{"key":"10.1016\/j.breast.2021.02.011_bib25","first-page":"77","article-title":"Subgroup Analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer","volume":"10","author":"Twelves","year":"2016","journal-title":"Breast Canc Basic Clin Res"},{"issue":"9769","key":"10.1016\/j.breast.2021.02.011_bib26","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2021.02.011_bib27","first-page":"57","article-title":"Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial","volume":"112","author":"Yuan","year":"2019","journal-title":"Eur J Canc (Oxford, England : 1990"},{"key":"10.1016\/j.breast.2021.02.011_bib28","first-page":"109","article-title":"Eribulin in the management of advanced breast cancer: implications of current research findings","volume":"9","author":"Kok","year":"2015","journal-title":"Breast Canc Basic Clin Res"},{"issue":"2","key":"10.1016\/j.breast.2021.02.011_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40273-014-0214-2","article-title":"Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal","volume":"33","author":"Greenhalgh","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.breast.2021.02.011_bib30","first-page":"1","article-title":"An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry","author":"Pouwels","year":"2020","journal-title":"Acta Oncol"},{"issue":"7","key":"10.1016\/j.breast.2021.02.011_bib31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1634\/theoncologist.2015-0002","article-title":"Treatment of metastatic breast cancer in a real-world scenario: is progression-free survival with first line predictive of benefit from second and later lines?","volume":"20","author":"Bonotto","year":"2015","journal-title":"Oncol"},{"issue":"9","key":"10.1016\/j.breast.2021.02.011_bib32","first-page":"652","article-title":"The hand-foot-syndrome associated with medical tumor therapy \u2013 classification and management","volume":"8","author":"Degen","year":"2010","journal-title":"JDDG J der Deutschen Dermatol Gesellschaft"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977621000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977621000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:49:08Z","timestamp":1783943348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977621000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":32,"alternative-id":["S0960977621000254"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2021.02.011","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2021.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}